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of a previously isolated lactobacillus strain — Lactobacillus fermentum UCO-979C — obtained from human gut.
Results: The strain tolerated pH 3.0; grew in the presence of 2% bile salts; produced lactic acid and hydrogen
peroxide; aggregated in saline solution; showed high hydrophobicity; showed high adherence to glass; Caco-2
and gastric adenocarcinoma human cells (AGS) cells; showed an efﬁcient colonization in Mongolian Gerbils;
and potently inhibited the growth and urease activity of H. pylori strains. L. fermentum UCO-979C signiﬁcantly
inhibited H. pylori-induced IL-8 production in AGS cells and reduced the viability of H. pylori. With regard to
innocuousness, the strain UCO-979C was susceptible to several antibiotics and did not produce histamine or
beta-haemolysis in blood agar containing red blood cells from various origins.
Conclusion: The results demonstrated that L. fermentumUCO-979C is a very good candidate as a probiotic for the
protection of humans against H. pylori infections.
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Probiotic protection against Helicobacter pylori1. Introduction
Probiotics are deﬁned as live microorganisms that can confer
beneﬁcial properties for health when consumed by individuals [1,2,
3]. To be considered as probiotics, microorganisms must meet several
requirements, including functional and safety aspects [4,5]. Probiotic
bacteria must be non-pathogenic and should produce antibacterial
substances to successfully compete with pathogens [6,7]. They
should also be tolerant to gastric acid and bile salts, and should be
able to colonize and persist in the gastrointestinal epithelium [8,9,10].
In addition, potential probiotic bacteria should meet safety aspects,
including the absence of transmissible antibiotic-resistance genes [11]
and the capacity to synthesize haemolysin or other toxic compounds
such as nocive biogenic amines (histamine, tyramine, putrescine,
cadaverine phenylethylamine or tryptamine) [12]. However, ifidad Católica de Valparaíso.
araíso. Production and hosting by Elbiogenic amines are produced, they must be present at low levels [4,
13,14].
Human probiotic bacteria that exert beneﬁcial effects on the
gastrointestinal tract include members of the genus Lactobacillus [2,10,
15]. These gram-positive bacteria are members of the normal human
microbiota [1] and are considered GRAS (generally recognized as safe)
microorganisms [16]. Lactobacillus strains have been successfully used
in prophylactic or therapeutic treatments of several diseases including
gastric disorders, inﬂammatory syndrome, bowel syndrome, gastric
cancer, or Helicobacter pylori infection [16,17,18]. Because H. pylori
colonizes in the gastric tract and is a causative agent of gastric
diseases, it is not surprising that several studies were carried out on
the effects of probiotics on H. pylori. Numerous in vitro studies
demonstrating bacterial inhibition were followed by preclinical and
clinical studies. These studies showed promising results of the use of
probiotics against H. pylori when administered alone or administered
together with the eradication treatment [18,19].
Considering that the Chilean population shows a high prevalence of
H. pylori-infected individuals [20,21] and of gastric cancer [22], our
laboratory has focused on the search of new and effective prophylaxissevier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
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the prophylaxis against H. pylori, and eradication therapy
shows increased failure mainly due to clarithromycin resistance of the
clinical isolates [23,24,25]. Thus, two ﬁelds of research arise as
promissory against H. pylori infection: the detection of natural
compounds with anti-H. pylori activity [26,27] and the isolation of
probiotic bacteria with anti-Helicobacter activities, such as Lactobacillus
spp. [18,24].
The present study aimed to establish a detailed characterization of
the probiotic properties and the anti-H. pylori activity of a previously
isolated lactobacillus strain — Lactobacillus fermentum UCO-979C —
obtained from human gut.
2. Material and methods
2.1. Isolation and identiﬁcation of L. fermentum UCO-979C
Lactobacillus UCO-979Cwas isolated from a human gastric biopsy in
the year 2007 [17]. The strain was identiﬁed as L. fermentum (95.0%)
through an API 50 CHL V5.2 kit. The ﬁnal identity of the strain as
L. fermentumwas conﬁrmed by the complete genome sequencing [28].
2.2. Control strains
Lactobacillus rhamnosusGG (ATCC53103), Lactobacillus johnsonii La1
and Lactobacillus casei Shirota reference strains were used as control for
the assay. The Shirota strain was isolated from a yogurt sample (Yakult)
obtained from a local supermarket at Montevideo, Uruguay. Strains GG
and La1 were kindly provided by Dr. Martin Gotteland (University of
Chile, Santiago, Chile).
Unless otherwise stated, all strains of Lactobacillus spp. were grown
in MRS (Man-Rogosa-Sharpe, Difco, France) agar or broth at 37°C
under microaerophilic conditions (10% CO2) for 48 h.
2.3. Physiological and functional properties of L. fermentum UCO-979C
2.3.1. Acid and bile tolerance
Acid tolerance was investigated as described by Kaushik et al. [29]
with minor modiﬁcations. Brieﬂy, 100 μL of a 24-h liquid culture of
L. fermentum UCO-979C or controls (L. rhamnosus GG or L. casei
Shirota) in MRS broth was inoculated in 10 mL of MRS adjusted
to pH 2 or 3. Cultures were incubated at 37°C under 10% CO2
atmosphere, and aliquots were obtained at 0, 1, 2, 3, and 24 h of
incubation to determine viable bacterial counts by the micro-drop
assay [30]. For studying bile tolerance, a similar assay was performed.
MRS broth was supplemented with 1.5 or 2.0% Oxgall bile salt
(Neogen, USA) [29]. Strains maintaining their viable count or growth
ability in the presence of bile salts were considered as tolerant.
2.3.2. Hydrophobicity
An organic solvent partitioning assay (MATH: Microbial Adhesion To
Hydrocarbons [31])was used to re-evaluate hydrophobicity as described
previously [17]. Brieﬂy, UCO-979C strain or controls (L. rhamnosus GG
and L. johnsonii La1) were grown in MRS broth for 24 h, collected by
centrifugation at 5000g for 5 min, and suspended in phosphate
buffered saline (PBS) supplemented with 3 M urea and 0.8 mMMgSO4
on glass tubes at OD400nm 0.8–1.0 and OD600nm 0.4–0.6. The bacterial
suspension (1.2 mL) was mixed with 0.3 mL of xylene, thoroughly
shaken in a Vortex for 2 min and allowed to stand for further 10 min.
The aqueous phase was separated and the OD at 400 nm and 600 nm
were measured. The hydrophobic percentage (% H) was calculated
using Ocaña et al. criteria [32] for classifying the strains as high
hydrophobicity (% H: 71–100), medium hydrophobicity (% H: 36–70)
or of low hydrophobicity (% H: 0–35).2.3.3. Saline aggregation test
This test was performed according to Ocaña et al. [32] without
modiﬁcations. Twenty microliters of a phosphate buffered saline (PBS)
cell suspension (1 × 109 CFU mL-1) of L. fermentum UCO-979C strain
or controls (L. rhamnosus GG or L. johnsonii La1) was mixed with 20 μL
of 2 M ammonium sulphate on the surface of a glass slide, allowed to
stand for 2 min before sealing the sample with a coverslip. Samples
were analysed using a light microscope to determine the saline
aggregation status of the strains and classiﬁed as non-aggregative,
medium aggregative and highly aggregative [32].
2.3.4. Glass adherence
L. fermentum UCO-979C strain or controls (L. rhamnosus GG or
L. johnsonii La1) were grown as described below. Cells were collected
by centrifugation and suspended in 20 mL MRS broth at a cellular
density equivalent to McFarland No.2 and incubated for 1 h. Sterile
glass slides were introduced into the culture ﬂask and incubated for
4 h, stained with crystal violet (0.1% w/v) for 5 min, washed and dried
for 10 min at room temperature. Samples were observed under a light
microscope (100× objective lens). The strains were classiﬁed as
non-adherent (less than 20 bacterial cells per ﬁeld), mildly adherent
(20–50 bacterial cells per ﬁeld), and strongly adherent (over 50
bacterial cells per ﬁeld).
2.4. Innocuousness assays for L. fermentum UCO-979C
2.4.1. Antibiotic susceptibility test
Susceptibility of L. fermentum UCO-979C and L. rhamnosus GG
to the antibiotics amikacin, ampicillin, amoxicillin, cefotaxime,
cefuroxime, ciproﬂoxacin, clarithromycin, chloramphenicol,
erythromycin, streptomycin, gentamicin, kanamycin, neomycin,
levoﬂoxacine, benzylpenicillin, rifampicin, sulphamethoxazole/
trimethoprim, tetracycline and vancomycin were determined by
an agar diffusion test as described previously [33]. The criteria of
Tang et al. [34] and Georgieva et al. [35] were used for classifying
the strains as susceptible or resistant to each antibiotic.
2.4.2. Determination of biogenic amines
Sample preparation was performed in 1 mL glass reaction vial. For
this purpose, 100 μL of culture supernatant ﬁltrate of Lactobacillus
UCO-979C strain or L. casei Shirota was dansylated by adding 400 μL of
carbonate–bicarbonate buffer (pH 10), 300 μL of acetone and 200 μL of
Dns-Cl solution. The mixture was vortexed for 30 s and then
incubated at 47°C for 60 min. This solution was ﬁltered through a
13-mm PVDF syringe mounted ﬁlter (0.45 μm) before HPLC injection.
Chromatography was performed using a Waters HPLC system
(Milford, USA) consisting of a 600 controller binary pump, a 717 plus
autosampler, a 2475 multi-λ ﬂuorescence detector, a 5CH column
oven and a VWR international L-7614 online degasser (West Chester,
Pennsylvania). Separation was carried out on a Waters C18 column
YMC-Pack ODS-A (150 mm × 4.6 mm, 5 μm) set at 45°C using
methanol (A) and water (B) as mobile phase. The ﬂow rate was of
1.2 mL min-1 achieving a complete separation of all biogenic amines
under study in 45 min. Detection was performed by ﬂuorescence
using 330 nm and 520 nm as excitation and emission wavelengths,
respectively.
2.4.3. Haemolysis assay
The strain UCO-979C was assayed for detecting haemolytic activity
on blood agar using Columbia agar base supplemented with 5%
blood from sheep, pig, and goat. The strain was incubated as
described above, and the results were expressed as positive for
β-haemolysis when a clear zone surrounding the colonies was
observed, γ-haemolysis-producing strain if no haemolysis was
observed surrounding the colonies or α-haemolysis-producing strain
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2.5. H. pylori inhibition by L. fermentum UCO-979C
Themethod of Sgouras et al. [33]withminormodiﬁcationswas used
to evaluate the anti-H. pylori 43504 activity [17]; two new reference
strains (H. pylori J99 and G27) were also used. Agar plates containing
20 mL of Columbia agar (Oxoid, UK) supplemented with 5%
deﬁbrinated horse blood were inoculated with H. pylori (ATCC43504,
J99 or G27 strain) by using a swab. Wells of 6 mm diameter were
made and 50 μL of the L. fermentum UCO-979C inoculum at a cellular
density of McFarland No. 2 was deposited in each well. Plates were
incubated at 37°C for 72 h under microaerophilic conditions
(Campygen, Oxoid, UK). To evaluate inhibition, the criteria of Gaudana
et al. [36] were followed, with the scorings as follows: no inhibition
(diameter of 1 mm or less), mild inhibition (diameter of more than
1 mm and up to 2 mm), strong inhibition (diameter of more than
2 mm and up to 5 mm), and very strong inhibition (diameters more
than 5 mm). The ﬁnal values of the inhibition diameters were
obtained by subtracting the well size (6 mm) to the inhibition zone
measured. All experiments were performed in triplicate. MRS broth
was used as negative control and L. casei Shirota, L. rhamnosus LGG
and L. johnsonii La1 were used as positive controls.
2.5.1. Death curves
The kinetics of H. pylori ATCC43504 inhibition by L. fermentum
UCO-979C was determined as follows: H. pylori 43504 was cultivated
on Columbia agar supplemented with 10% whole horse blood and
incubated for 72 h at 37°C under 10% CO2. The colonies obtained were
suspended in 3 mL Brain–Heart Infusion (BHI) broth at McFarland
No. 2. A 1.8-mL suspension was mixed with 200 μL of a cell-free
supernatant of L. fermentum UCO-979C obtained by growing the strain
for 24 h in MRS followed by ﬁltration through a 0.22-μm diameter pore
ﬁlter. Viable cell counts of H. pylori were determined at 0, 3, and 24 h
(ﬁrst experiment) and at 0, 0.5, 1, 1.5, 2, 4, 5, and 6 h (second
experiment) after the challenge by removing 20 μL aliquots in triplicate
at each sampling time and plating it in Columbia Agar supplemented
with 10% horse blood. A killing curve with amoxicillin was used as
control for bacterial death. Both sterile MRS broth and BHI broth were
also used as control formeasuring endogenous anti-H. pylori activity [37].
2.5.2. Urease inhibition assay
Urease inhibition assay was performed as described by Sgouras et al.
[33] with minor modiﬁcations. A 1-mL suspension of McFarland No. 2
inoculum of H. pylori ATCC43504 grown in BHI broth was mixed with
100 μL of a cell-free supernatant obtained after ﬁltering (using a
0.22-μm membrane) a 48-h culture of Lactobacillus UCO-979C strain.
Amoxicillin (20 μg mL-1) was used as positive control and Brain–Heart
Infusion (BHI, Oxoid, UK) broth as negative control. Each suspension
was incubated at 37°C under 10% CO2 atmosphere and samples of
150 μL were obtained after 0, 3 and 24 h of incubation. A 100-μL
suspension was mixed with 900 μL of 20% urea in 10 mM phosphate
buffer, pH 6.5 and 0.012% phenol red. The mixture was incubated for
additional 1 h and the absorbance at 550 nm was recorded to
establish the percentage of urease inhibition.
2.5.3. Adherence and protection assays with AGS cells
AGS cell, an adherent human gastric adenocarcinoma epithelial cell
line, was used to further evaluate L. fermentum UCO-979C strain. The
adherence of H. pylori to AGS cells was performed using the phenol
red method according to Pastene et al. [27]. Brieﬂy, AGS cells were
cultured in T-75 ﬂasks containing Roswell Park Memorial Institute
medium (RPMI) 1640 medium supplemented with 10% foetal
calf serum (FCS) and 1% antibiotics solution (10 U/mL penicillin,
10,000 μg/mL streptomycin and 25 μg/mL amphotericin B) for 4 duntil more than 90% conﬂuence was reached. AGS cells were
trypsinized (0.25% trypsin and 2.21 mM ethylenediaminetetraacetic
acid (EDTA) solution), counted using trypan blue and a Neubauer
chamber [28] and adjusted to a concentration of 5 × 103 CFU mL-1.
The potential protection provided by L. fermentum UCO-979C to AGS
cells infected byH. pyloriwas assessed by adhesion assays. AGS cellswere
cultured in a 96-well microplates and treated with the UCO-979C strain
at different concentrations: 105, 106, 107, 108 or 109 CFU mL-1. After
4 h, AGS cells were infected with H. pylori ATCC 43504 (McFarland No.
2). AGS cells infected only with strain ATCC 43504 were used as
control. After 4 h of incubation, the supernatants were removed and
conserved for cytokine analysis (-20°C) and, phenol red indicator was
added (0.003% phenol red, 2% urea, pH 6.8). Finally, microplates were
read using a spectrophotometer at 570 nm wavelength.2.5.4. Regulation of IL-8 production
To determine the possible anti-inﬂammatory effect of L. fermentum
UCO-979C on AGS cells during H. pylori ATCC 43504 infection, the
levels of IL-8 were measured using an enzyme-linked immunosorbent
assay (ELISA). The cellular supernatants obtained in the experiments
as described in Section 2.5.3 were kept at -20°C to be used for IL-8
production analysis. After supernatants were thawed, IL-8 was
quantiﬁed using the DuoSet kit (R&D Systems) following the
manufacturer's instructions.2.6. Analysis of antimicrobial compounds synthetized by L. fermentum
UCO-979C
2.6.1. L-lactic acid determination
L-lactic acid stock solution was prepared in ultra-pure water at a
concentration of 1 mg/mL and chromatography was performed on
HPTLC plates from Merck, coated with 0.2 mm of silica gel 60 F254. A
calibration curve with L-lactic acid between 3 and 15 μg/mL was used.
The samples of L. fermentum UCO-979C, L. rhamnosus and L. casei
Shirota were centrifuged at 15000g for 5 min, and the supernatant
ﬁltrated through a 0.45-μm pore diameter ﬁlter mounted in a syringe
prior to be used in the assays. Samples (2–3 μL) and 3–15 μL standard
of L-lactic acid were applied to the column by using an Automatic TLC
Sampler (ATS4) from CAMAG (Muttenz, Switzerland).
Chromatography was performed using a mixture of diisopropyl
ether:formic acid:water (80:15:5 v/v) as mobile phase. The plates
were then dried under a stream of warm air. Lactic acid was
detected after a post-chromatographic derivatization with an
ethanolic solution of bromophenol blue (0.5 mg mL-1) and 0.1
aqueous NaOH is carefully added until the colour of the solution
changes to blue. The plates were then heated on a TLC plate heater
(CAMAG) for 2 min at 100°C. Scanning was performed using a TLC
Scanner 3 (CAMAG) in visible absorption mode at 430 nm. All
instruments were controlled by WinCats software 1.4.2 Planar
Chromatography Manager (CAMAG).2.6.2. Hydrogen peroxide (H2O2) production
The semiquantitative method described by Felten et al. [38] was
used for determining H2O2 production. Brieﬂy, the strains of
lactobacilli were inoculated on MRS agar supplemented with 3, 3′, 5,
5′-tetramethylbenzidine and H2O2, incubated during 48 h at 37°C
under 10% CO2 and the colour developed in colonies was recorded. A
strain of Enterococcus faeciumwas used as a positive control.
The criterion applied for the interpretation of the results was as
follows: negative synthesis (-), white colonies; low synthesis (+),
light blue colonies; moderated synthesis (++), dark light blue
colonies; and strong synthesis (+++), the colonies show a blue
colour [38].
Table 1
Lactobacillus strains tolerance to pH 3.0.
Strain Viable counts (CFU/mL) at pH 3.0
Before exposure 0 h 1 h 2 h 3 h 24 h
L. fermentum UCO-979C 1.5 × 108 8.0 × 106 8.3 × 106 5.4 × 106a 4.4 × 106 4.5 × 106
L. casei Shirota 1.0 × 108 7.2 × 107 6.2 × 107 7.1 × 107a 9.9 × 107 1.0 × 108
L. rhamnosus GG 1.9 × 106 2.4 × 106 2.7 × 106 2.9 × 106b 2.6 × 106 2.1 × 106
Different superscripts (a and b) indicate signiﬁcant differences (P b 0.05). For details, see Material and methods.
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Six female Mongolian gerbils (Meriones unguiculatus) (24- to
28-weeks-old) were divided in two groups of three animals each: one
used as the challenge group and the second was used as the control
group. The gerbils were obtained from the closed colony kept at the
Laboratory of Pharmacognosy (Universidad of Concepción, Chile). All
experiments were carried out in compliance with the Guide for Care
and Use of Laboratory Animals and approved by the Ethical
Committee of Animal Care at the University of Concepción, Chile and
in accordance with the U.K. Animals and associated guidelines, EU
Directive.
During the days of study, the animals were kept in controlled
environmental conditions with light dark cycles of 12 h, and isolated
in plastic cages to minimize contact with environmental particles. All
animals were fed with balanced conventional diet and sterilized water
ad libitum. The animals were fasted 20 h before receiving inoculation
of probiotic bacteria L. fermentum UCO-979C. Labelling of L. fermentum
UCO-979C was performed by suspending bacterial pellets in PBS
buffer to a concentration of McFarland No. 4. Then, 10 μL of
ﬂuorescein isothiocyanate (FITC) was added, and the suspension was
incubated at 37°C in dark for 1 h. Bacterial suspensions were
centrifuged twice at 5000 rpm for 5 min in PBS. The animals were
anaesthetized by isoﬂurane inhalation (Baxter Forane 100%). Once
animals were anaesthetized, 1 mL of FITC-labelled L. fermentum
UCO-979C (McFarland No. 4) was inoculated orally into their stomach.
The challenge group was inoculated with 1 mL of the strain UCO-979C
(1.2 × 109 CFU mL-1) labelled with FITC. The control group was
inoculated with only 1 mL of PBS. The animals were euthanized after
10 h post-inoculation, and their stomachs were excised and observed
under ﬂuorescence using the UVP i-Box Scientia Small Animal Imaging
System (California, USA).2.7.1. L. fermentum UCO-979C bacterial counts
For bacterial counts, another group of six gerbils was used. The
animals were managed and challenge as mentioned above, but in this
case, the strain was not labelled with FITC. Pyloric antrum and corpus
samples were aseptically obtained 14 d after the inoculation; the
samples were homogenized with PBS, and 20 μL of macerated organs
was collected and used for microdroplet technique on MRS agar. The
samples were incubated at 37°C for 24 h under microaerophilic
conditions (10% CO2) and bacterial counts were determined.Table 2
Lactobacillus strains tolerance to 2.0% bile salts.
Strain Viable counts (CFU/mL)
Before
exposure
0 h 1 h 2 h 24 h
L. fermentum
UCO-979C
2.9 × 106a 6.4 × 106a 4.2 × 106a 4.2 × 106a 2.6 × 107b
L. casei Shirota 4.1 × 106 4.9 × 106 6.1 × 106 6.3 × 106 3.8 × 106
L. rhamnosus GG 3.1 × 106 5.9 × 106 3.9 × 106 7.1 × 106 3.0 × 107
Different superscripts (a and b) indicate signiﬁcant differences (P b 0.05). For details, see
Material and methods.2.8. Statistical analysis
Experiments were performed in triplicate, and the results were
expressed as mean ± standard deviation (SD). After veriﬁcation of
the normal distribution of data, 2-way ANOVA was used. Tukey's post
hoc (for pair wise comparisons of the means) was used to test
for differences between the groups. Differences were considered
signiﬁcant at P b 0.05.
3. Results
3.1. Physiological and functional properties of L. fermentum UCO-979C for
its potential use as probiotic
Several physiological properties of L. fermentumUCO-979C related to
its probiotic potential were evaluated, including tolerance to acid and
bile, hydrophobicity, saline aggregation and in vitro adherence. Bile
and pH tolerance tests showed that L. fermentum UCO-979C had a
similar behaviour compared to the control strains L. casei Shirota and
L. rhamnosus GG. All the strains were susceptible to pH 2 since the
acidic medium inhibited bacteria prior to 1 h of incubation (data not
shown). In contrast, all the strains remain viable after 24 h of
incubation at pH 3 (Table 1). A sudden decrease of two logarithms in
the count of viable L. fermentum UCO-979C was consistently detected
at the beginning of the exposure to pH 3. No statically signiﬁcant
differences (P b 0.05) were observed among the viable counts of the
UCO-979C strain during the 24 h of exposure to pH 3. In addition, bile
tolerance test indicated that all the strains were resistant to 2.0% of
bile salts (Table 2).
L. fermentum UCO-979C showed both high hydrophobicity and
positive saline aggregation (Table 3), indicating that this strain could
have an increased capacity for cellular adherence. In fact, L. fermentum
UCO-979C was highly adherent in the glass assay and to Caco-2 cells
in culture, similar to L. rhamnosus GG and L. johnsonii La1.
3.2. Safety assessment of L. fermentum UCO-979C for its potential use as
probiotic
To evaluate the safety of L. fermentum UCO-979C, antibiotic
resistance, haemolytic activity and production of biogenic amines
were studied. The probiotic strain was susceptible to all the 19
antibiotics assayed with the exception of benzylpenicillin (Table 4),
suggesting that this strain does not harbour resistance plasmids. On
the other hand, the commercial probiotic strain L. rhamnosus GG used
as control showed resistance to vancomycin, kanamycin, streptomycin
and sulphamethoxazole/trimethoprim (Table 4).Table 3
Physiological properties of Lactobacillus strains.
Assay L. fermentum
UCO-979C
L. johnsonii
La1
L. rhamnosus
GG
Hydrophobicity Strong Strong Moderate
Saline aggregation test Positive Negative Negative
Glass adherence ++ ++ ++
Table 4
Antibiotic susceptibility proﬁle of Lactobacillus strains.
Antibiotic (μg) Strains
L. fermentum
UCO-979C
L. rhamnosus
GG
Amikacin 30 S S – MS
Amoxicillin 10 – SS – MS
Ampicillin 10 – SS – S
Cefotaxime 30 – SS – SS
Cefuroxime 30 – S – S
Ciproﬂoxacin 5 S – S SS
Clarithromycin 5 – S – SS
Chloramphenicol 30 S SS S S
Erythromycin 15 – S S SS
Streptomycin 10 S S R MS
Gentamicin 10 S S S S
Kanamycin 30 – S – R
Levoﬂoxacin 5 – S – SS
Neomycin 30 – S – S
Penicillin G 10 R MS S S
Rifampicin 5 – S – SS
Sulfatrimethoprim 25 S S R R
Tetracycline 30 S SS S SS
Vancomycin 30 – MS R R
C1: criterion 1, Tang et al. [34]; C2: criterion 2, Georgieva et al. [35]; MS: moderately
susceptible; S: susceptible; SS: strongly susceptible; R: resistant.
Table 6
Antimicrobial activity spectrum exhibited by various lactobacilli on Helicobacter pylori
strains.
Lactobacillus strains
Helicobacter pylori strains
ATCC43504 J99 G27
L. rhamnosus GG 2.3 ± 0.05a ++ 2 ± 0.15 + 3 ± 0.12 ++
L. casei Shirota 3.8 ± 0.05 ++ 3.5 ± 0.05 ++ 4 ± 0.1 ++
L. johnsonii La1 2.7 ± 0.05 ++ 2.5 ± 0.15 ++ 3 ± 0.05 ++
L. fermentum
UCO-979C
5.1 ± 0.05 +++ 5 ± 0.15 ++ 6 ± 0.1 +++
The inhibition zones 1mm, 2mm, 2–5mmandmore than 5mmwere classiﬁed as strains
of no (+/-), mild (+), strong (++) and very strong (+++) inhibition, respectively
(Gaudana et al. criterion [36]).
a Results are expressed as mean ± standard deviation of three independent biological
replicates.
79A. García et al. / Electronic Journal of Biotechnology 25 (2017) 75–83Our strain UCO-979C showed α-haemolysis in blood agar assays,
which is indicative of a non-β-haemolytic strain according to the
criteria of Peres et al. [8].
As shown in Table 5, the total content of biogenic amines was 5.43
and 8.59 mg/L for L. casei Shirota and L. fermentum UCO-979C,
respectively. The Bonferroni statistical test revealed no signiﬁcant
differences (P N 0.05) between Shirota and UCO-979C strains.
Interestingly, histamine, which is the most important biogenic amine,
was not detected in any of the strains.3.3. Anti-H. pylori activity of L. fermentum UCO-979C
The UCO-979C strain showed the highest antibacterial activity
against the three H. pylori strains used as indicators. Moreover, the
antibacterial activity of L. fermentum UCO-979C was higher than
the activity of the reference L. rhamnosus GG, L. casei Shirota and
L. johnsonii La1 strains (Table 6). Inhibition kinetics studies further
showed that L. fermentum UCO-979C exhibited an antibacterial
activity against H. pylori ATCC 43504 that was similar to that shown
by amoxicillin used as positive control (Fig. 1a). Thus, in accordance
with the bacterial death criteria of Pearson et al. [37], the effect of
UCO-979C strain at 24 h can be considered as lethal for H. pylori. On
the other hand, after repeating this assay at shorter time intervals and
by using the same Pearson criteria [37], the inhibition of H. pylori
was still observed after 4 h of treatment with L. fermentum UCO-979C
(Fig. 1b).Table 5
Biogenic amine content in MRS broth.
Biogenic amines (mg L-1) Strains
L. fermentum UCO-979C L. casei Shirota
2-Phenylethylamine 2.70 ± 0.16 1.07 ± 0.05
Putrescine 2.34 ± 0.29 1.56 ± 0.19
Cadaverine 1.44 ± 0.07 1.74 ± 0.11
Histamine ND ND
Tyramine 0.44 ± 0.04 0.53 ± 0.12
Spermidine TR TR
Spermine 1.68 ± 0.49 0.53 ± 0.01
Total 8.59 5.43
ND: not detected, TR: traces (not quantiﬁable).Urease activity of H. pylori ATCC43504 showed a slight decrease in
the presence of amoxicillin (Fig. 2). This inhibition effect was more
intense when the cell-free supernatant obtained from a culture of
L. fermentum UCO-979C was used, showing that a diffusible molecule
should be present in this supernatant.
The ability of L. fermentum UCO-979C to inhibit H. pylori adhesion
was evaluated in AGS cells. The results demonstrated that the
UCO-979C strain could decrease H. pylori adhesion to AGS cells in a
dose-dependent manner (Fig. 3). The lowest H. pylori adherence to
AGS cells occurred when L. fermentum UCO-979C was used at a
concentration of 108 or 109 CFU mL-1 (P b 0.05) (Fig. 3).
The capacity of L. fermentum UCO-979C to modulate IL-8 production
in AGS cell was also evaluated. Treatment of gastric cells with the
UCO-979C did not induce signiﬁcant changes in the production of IL-8
(Fig. 4). Challenge of AGS cells with H. pylori ATCC 43504 signiﬁcantly
increased the levels of IL-8 in agreement with the capacity of the
pathogen to mount a robust inﬂammatory response in gastric
cells. However, when AGS cells were colonized with L. fermentum
UCO-979C previous to H. pylori challenge, a signiﬁcant decrease in IL-8
production was observed (Fig. 4).
3.4. Analysis of the production of antimicrobial compounds by L. fermentum
UCO-979C
In vitro analysis showed that the lactic acid content in the growth
medium of L. fermentum UCO-979C and L. casei Shirota was
3.149 mg/mL and 2.764 mg/mL, respectively, with no statistical
differences among the strains studied. Similarly, both strains produced
+++ H2O2, which according to the criteria of Felten et al. [38] is
high, and no signiﬁcant differences were observed between the two
strains.
3.5. Colonization assays in Mongolian gerbils
Fluorescence studies demonstrated that L. fermentum UCO-979C
strain adheres to the gastric mucosa of Mongolian gerbils (Fig. 5). This
adhesive capacity of the UCO-979C strain was conﬁrmed by the
determination of bacterial counts. Animals were initially inoculated
with 1.2 × 109 CFU mL-1 of the UCO-979C strain and after 14 d, we
detected a count of 2.5 × 107 and 2.8 × 107 CFU mL-1 in the pyloric
antrum and corpus of the gerbil stomachs, respectively.
4. Discussion
Among the pathogenic bacteria that can colonize and affect the
human stomach, H. pylori is the most important pathogen. H. pylori
selectively colonizes stomach epithelium, and in some individuals,
early infection and persistence of bacteria cause chronic gastric
inﬂammation and tissue damage, changes that could progress to
severe diseases such as peptic ulcer or gastric adenocarcinoma [38]. In
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Fig. 1. Inhibition kinetics of Lactobacillus fermentum UCO-979C strain against Helicobacter pylori ATCC 43504. (a) Samples taken at 3 different times from 0 to 24 h. (b) Samples taken at 6
different times from 0 to 6 h.
80 A. García et al. / Electronic Journal of Biotechnology 25 (2017) 75–83addition to pathogenic bacteria, the combination of traditional
analytical tools and culture-independent molecular methods has
shown wide diversity of the bacterial microbial ecosystem of the
stomach. This fact shows that although the extremely acidic
environment of the stomach could theoretically prevent bacterial
colonization, it does not mean that some bacteria have not adapted to
these extreme conditions, such as acidophilus bacteria that require or
can survive at low pH [39,40]. This fact implies that the microbiota of
the gastric mucosa can be an interesting source of potential probiotic
strains with the ability to prevent or reduce the colonization of
pathogens such as H. pylori.
Interestingly, several studies were carried out on the effects of
beneﬁcial probiotic bacteria on H. pylori. Numerous in vitro studies
demonstrating bacterial inhibition were followed by preclinical and
clinical studies that indicated only partial efﬁcacy of probiotics against
H. pylori when administered alone, but increase in efﬁcacy and/or
reduction of side effects when probiotics were administered together
with the eradication treatment [19]. Moreover, few studies were
performed with probiotics strains isolated from human stomach. In
the present study, we aimed to characterize a potential probiotic
property of L. fermentum strain isolated previously from a human
stomach.
To be considered as a potential probiotic for human use, bacterial
strains must comply with a series of characteristics grouped into two
main categories: functional properties and innocuousness or safety.
Several studies have been performed to determine whether the
candidate probiotic strain is not toxic and whether it possesses the
claimed properties [4,3,10]. Therefore, we studied several characteristics
of L. fermentum UCO-979C to determine its safety and functional
capacities.0.4
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Fig. 2. Inhibitory activity of Lactobacillus fermentum UCO-979C strain over the activity of
Helicobacter pylori urease. Samples taken at times 0, 3 and 24 h.The present study demonstrated that the UCO-979C strain was
resistant to one antibiotic: penicillin G; this would be an undesirable
property [23,41]. Nevertheless, penicillin resistance has been observed
in diverse Lactobacillus strains, and it is usually codiﬁed in the
chromosome, suggesting a low probability of transferring it to other
bacterial cells [42]. Additionally, the capacity of the UCO-979C strain
to produce biogenic amines was also evaluated. The increase in the
levels of biogenic amines in serum, especially histamine, is deleterious
for human health. These amines can cause several detrimental effects
including hypotension, hypertension, nausea, diarrhoea, headache,
and respiratory or skin problems [43,44,45]. It must be emphasized
that L. fermentum UCO-979C did not produce detectable levels of
histamine. These results clearly indicate that L. fermentum UCO-979C
could be used as a safe probiotic microorganism.
Tolerance to acid and bile salts are desirable properties in bacterial
species to be considered as human probiotics because of the stress
conditions found in the gastrointestinal tract of humans. In this regard,
probiotic microorganisms thought to colonize the stomach region
should be tolerant to pH 3 [6,40] or, at least, tolerant to pH 4, which is
the pH of the gastric mucus layer. New species belonging to the genus
Lactobacillus sp. isolated from human stomach mucosa have been
described (Lactobacillus gastricus, Lactobacillus antri, Lactobacillus
kalixensis and Lactobacillus ultunensis) that show high resistance
to acidic conditions allowing them to persist in this rigorous
environment [46,47]. As shown here, L. fermentum UCO-979C strain
survived at pH 3 for 24 h and it had a similar behaviour to that
observed for other probiotics strain such as L. rhamnosus GG with
respect to its tolerance to pH and bile salts. Moreover, the in vivo
experiments in Mongolian gerbils clearly demonstrated the capacity of
the UCO-979 strain to colonize and survive in the gastric mucosa.0%
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Fig. 3. Percentage of Helicobacter pylori (ATCC 43504) adherence on AGS cells previously
colonized by Lactobacillus fermentum UCO-979C (preventive treatment) strain at
different bacterial concentrations.
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Fig. 4. Determination of IL-8 levels produced by AGS cells infected with H. pylori ATCC
43504 or/and colonized with Lactobacillus fermentum UCO-979C and non-infected
(control) by using an ELISA assay.
81A. García et al. / Electronic Journal of Biotechnology 25 (2017) 75–83We demonstrated that L. fermentum UCO-979C has several
characteristics making it an excellent candidate as a probiotic to
prevent infection by H. pylori. The UCO-979C strain inhibited
bacterial pathogen growth, reduced H. pylori urease activity,
decreased pathogen adhesion to gastric cells and beneﬁcially
regulated the inﬂammatory response. There are several reports
describing probiotic strains with anti-H. pylori activity through the
production of antimicrobial compounds such as bacteriocins,
autolysins and organic acids [7,48]. In this regard, inhibition of H.
pylori by the production of lactic acid has been reported in
Lactobacillus salivarius, Lactobacillus acidophilus, L. rhamnosus and L.
casei strain Shirota [49], in both in vitro and animal studies. Lactica
c
Fig. 5. Adherence of Lactobacillus fermentumUCO-979C strain to the stomachs ofMongolian gerb
stomach caused by the adherence of the UCO-979C strain.acid, in addition to its antimicrobial effect by the decrease in pH,
could inhibit the urease enzyme of H. pylori.
L. fermentum UCO-979C could reduce colonization of H. pylori and
decrease the production of the inﬂammatory chemokine IL-8 in
human gastric epithelial cells. Human immune response has an
important role in the development of serious diseases after H. pylori
infection since increased pro-inﬂammatory cytokine expression was
found in the gastric mucosa of infected patients [50]. Regulation of
H. pylori-induced inﬂammation was reported to play important roles in
the prevention of chronic gastric damage and cancer. H. pylori infection
can activate NF-kB in gastric epithelium cells and subsequently
up-regulate IL-8 gene transcription that greatly contributes to disease
evolution. On the other hand, some probiotics, including lactobacilli,
have previously been shown to decrease inﬂammatory markers in
H. pylori infection models both in vitro and in vivo [51,52]. Here, we
showed that L. fermentum UCO-979C could induce a signiﬁcant
reduction in IL-8 production in H. pylori-infected cells, indicating its
potential as a beneﬁcial immunomodulator. More detailed studies
about L. fermentum UCO-979C immunomodulatory properties would
allow us to include this strain in the group of bacteria known as
immunobiotics [53,54].
In conclusion, the results presented here indicate that L. fermentum
UCO-979C is a good candidate for use as human probiotic for gastric
protection against H. pylori, since this strain can tolerate the stress
conditions of this habitat in addition to its capacity to produce
antimicrobial compounds and to beneﬁcially modulate inﬂammatory
response. In this regard, it should be noted that antimicrobial and
immunomodulatory activities are independent properties. In fact, it
was reported that some probiotic bacteria have a positive effect ond
b
ils detected by ﬂuorescence. (a) and (b): control stomach; (c) and (d): ﬂuorescence in the
82 A. García et al. / Electronic Journal of Biotechnology 25 (2017) 75–83H. pylori-associated inﬂammationwithout clearing the infection [55,56].
L. fermentum UCO-979C that harbours both these properties has a high
probability of functioning as an effective anti-Helicobacter probiotic.
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